Table 3 Summary of molecular alterations in pancreatic acinar cell carcinomas reported in the literature
From: Analysis of LKB1 mutations and other molecular alterations in pancreatic acinar cell carcinoma
Genetic alteration | Cases studied | Abnormal cases (%) | References |
|---|---|---|---|
KRAS | 36 | 1 (3%) | |
TP53 | 69 | 0 (0%) | |
CDKN1A mutation | 6 | 0 (0%) | |
SMAD4 | 35 | 0 (0%) | |
APC/CTNNB1 | 17 | 4a (24%) | |
MSI | 13 | 3b (23%) | |
Gain at 1q, 12p, Xq, | 6 | NA (50–60%) | |
Loss at 16p, 16q | 6 | NA (50%) | |
Loss at 1p, 4q, 17p | 9 | NA (>70%) | |
Loss at 11q, 13q, 15q, 16q | 9 | NA (60–70%) | |
Loss at 3q, 6q, 8q, 18q, 21q | 9 | NA (50–60%) | |
Loss of 11p | 12 | 6 (50%) |
